covid-19 information vaccine

Akers, Premas note positive proof-of-concept data of Covid-19 vaccine

Reading now: 798
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Akers Biosciences and Premas Biotech have reported positive proof-of-concept data from animal studies of their PRAK-03202 vaccine candidate against Covid-19.

A four-week test in mice met its primary endpoints of safety and immune response, said the companies. The vaccine candidate was well-tolerated and safe in the animals, with an encouraging immune response.

During the preclinical study, 50 mice across ten cohorts received 5, 10 and 20μg of the vaccine candidate, found to be generally well-tolerated and safe at all doses, without any adverse events.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA